The aim of this project was to conduct the first known clinical trial of the short-term (i.e. 6 weeks) efficacy of cranberry juice (Vaccinium spp. not specified) on the neuropsychologic functioning of cognitively intact older adults. Fifty community dwelling, cognitively intact volunteers, ≥ 60 years old, who reported no history of dementia or significant neurocognitive impairments, participated in this study. A 6-week, double-blind, placebo-controlled, randomised, parallel-group clinical trial was used. Participants were randomly assigned to receive either 32 ounces/day of a beverage containing 27% cranberry juice per volume (n=25) or placebo (n=25) for 6 weeks, and administered a series of neuropsychologic tests at both pretreatment baseline and again after 6 weeks of either cranberry juice or placebo treatment to assess treatment-related changes. Two-factor, mixed ANOVA revealed no significant group (cranberry juice and placebo) by trial (pretreatment baseline and end-of-treatment assessments) interactions across all of the neuropsychologic tests and measures used in this study when a Bonferroni corrected alpha level was used to correct for multiple comparisons (i.e. 0.05/17 group by trial comparisons=0.003). Pearson chi-square analyses of the groups’ self-reported changes over the 6-week treatment phase in their ability to remember, thinking processes, moods, energy levels and overall health on the Follow-up Self-report Questionnaire revealed no significant relationships. However, a non-significant trend (X2(1)=2.373, P=0.123) was noted for participants’ self-reported overall abilities to remember from pretreatment baseline to the end-of-treatment assessment. Specifically, more than twice as many participants in the cranberry group (n=9, 37.5%) rated their overall ability to remember by treatment end as ‘improved’ as compared to placebo controls (n=4, 17.4%).